Menetrier's disease: Long-term remission with lanreotide.

Date publication

septembre 2015

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CADIOT Guillaume , Pr HOEFFEL Christine

Tous les auteurs :
Heurgue-Berlot A, Feron T, Jazeron JF, Hoeffel C, Diebold MD, Cadiot G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26382280

Résumé

Menetrier's disease is a rare hypertrophic gastropathy, causing protein leak. An overexpression of transforming growth factor alpha is involved. In inhibiting the epidermal growth factor receptor, cetuximab and somatostatin analogues are the two most promising treatments, allowing to avoid radical gastrectomy. We report the case of a patient with a sustained clinical remission after treatment with lanreotide, but without complete endoscopic healing. We discuss the available therapeutic options and present a literature review of somatostatin analogues for the treatment of Menetrier's disease.

Référence

Clin Res Hepatol Gastroenterol. 2015 Sep 14. pii: S2210-7401(15)00203-X